Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Therapy

High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)

Leukemia volume 20, pages 814–819 (2006)Cite this article

Abstract

The most appropriate treatment for lymphoblastic lymphomas (LL) remains uncertain. We treated 27 patients with newly diagnosed LL according to an LMT-89 protocol, which is a modified version of the LMT-81 protocol previously reported in pediatric patients. The median age was 31 years. Mediastinal enlargement was present in 25/27 patients, with pleural effusion in 12. Four patients had central nervous system involvement and 12 had bone marrow involvement and 24/27 (89%) had advanced Ann Arbor stage III–IV disease. Complete remission (CR) was achieved in 20/27 patients, unconfirmed complete remission in three patients (residual mediastinal lesion on computed tomography scan) and four failed induction therapy (ORR: 85%). Twelve patients (44%) remained in continuous CR with a median follow-up of 95 months. Survival at 3 years (when all the events occurred in our series) was 63%. Bone marrow involvement was associated with a poor outcome. Overall survival was 85±20% in patients without bone marrow involvement compared to 37±30% in patients with bone marrow involvement. The Ann Arbor stage, age and serum lactate dehydrogenase level did not influence outcomes. This LMT-89 protocol is a safe regimen and is highly effective in advanced LL without bone marrow involvement.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Armitage JO, Weisenburger DD . New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795.

    Article  CAS  Google Scholar 

  2. Thomas D, Kantarjian H . Advances in the treatment of adult leukemia, Part II. Hematol Oncol Clin North Am 2001; 15: 51–95.

    Article  CAS  Google Scholar 

  3. Coleman CN, Picozzi Jr VJ, Cox RS, McWhirter K, Weiss LM, Cohen JR et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 1628–1637.

    Article  CAS  Google Scholar 

  4. Picozzi Jr VJ, Coleman CN . Lymphoblastic lymphoma. Semin Oncol 1990; 17: 96–103.

    PubMed  Google Scholar 

  5. Catovsky D, Goldman JM, Okos A, Frisch B, Galton DA . T-lymphoblastic leukaemia: a distinct variant of acute leukaemia. Br Med J 1974; 2: 643–646.

    Article  CAS  Google Scholar 

  6. Bernard A, Boumsell L, Reinherz EL, Nadler LM, Ritz J, Coppin H et al. Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood 1981; 57: 1105–1110.

    CAS  PubMed  Google Scholar 

  7. Le Gouill S, Lepretre S, Briere J, Morel P, Bouabdallah R, Raffoux E et al. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia 2003; 17: 2220–2224.

    Article  CAS  Google Scholar 

  8. Colgan JP, Andersen J, Habermann TM, Earle JD, O'Connell MJ, Neiman RS et al. Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma. Leuk Lymphoma 1994; 15: 291–296.

    Article  CAS  Google Scholar 

  9. Nathwani BN, Diamond LW, Winberg CD, Kim H, Bearman RM, Glick JH et al. Lymphoblastic lymphoma: a clinicopathologic study of 95 patients. Cancer 1981; 48: 2347–2357.

    Article  CAS  Google Scholar 

  10. Hoelzer D, Gökbuget N, Digel W, Faak T, Kneba T, Reutzel R et al. Leukemia GMSAAL: outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002; 99: 4379–4385.

    Article  CAS  Google Scholar 

  11. Thomas DA, O'Brien SM, Cortes J, Giles FJ, Faderl S, Verstovsek S et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004; 104: 1624–1630.

    Article  CAS  Google Scholar 

  12. Bernasconi C, Brusamolino E, Lazzarino M, Morra E, Pagnucco G, Orlandi E . Lymphoblastic lymphoma in adult patients: clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphoblastic leukemia. Ann Oncol 1990; 1: 141–146.

    Article  CAS  Google Scholar 

  13. Slater DE, Mertelsmann R, Koziner B, Higgins C, McKenzie S, Schauer P et al. Lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 57–67.

    Article  CAS  Google Scholar 

  14. Bouabdallah R, Xerri L, Bardou VJ, Stoppa AM, Blaise D, Sainty D et al. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol 1998; 9: 619–625.

    Article  CAS  Google Scholar 

  15. Zinzani PL, Bendandi M, Visani G, Gherlinzoni F, Frezza G, Merla E et al. Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma 1996; 23: 577–582.

    Article  CAS  Google Scholar 

  16. Morel P, Lepage E, Brice P, Dupriez B, D'Agay MF, Fenaux P et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 1992; 10: 1078–1085.

    Article  CAS  Google Scholar 

  17. Patte C, Kalifa C, Flamant F, Hartmann O, Brugieres L, Valteau-Couanet D et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 1992; 20: 105–113.

    Article  CAS  Google Scholar 

  18. Attarbaschi A, Mann G, Dworzak M, Wiesbauer P, Schrappe M, Gadner H . Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: significance and therapy response. Med Pediatr Oncol 2002; 39: 558–565.

    Article  Google Scholar 

  19. Murphy SB, Hustu HO . A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma. Cancer 1980; 45: 630–637.

    Article  CAS  Google Scholar 

  20. Milpied N, Ifrah N, Kuentz M, Maraninchi D, Colombat P, Blaise D et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 1989; 73: 82–87.

    Article  CAS  Google Scholar 

  21. Baro J, Richard C, Sierra J, Garcia-Conde J, Garcia Larana J, Rocha E et al. Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy. Bone Marrow Transplant 1992; 10: 33–38.

    CAS  PubMed  Google Scholar 

  22. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F et al. Autologous vs allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690–1695.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Lorna Saint Ange for editing.

Author information

Authors and Affiliations

  1. Département de Médecine, Institut Gustave Roussy, Villejuif, France

    E Jabbour, C Fermé, J H Bourhis, J M Vantelon, P Arnaud & V Ribrag

  2. Département de Biostatistique, Institut Gustave Roussy, Villejuif, France

    S Koscielny & N Peslin

  3. Département de Médecine, Centre Léon Bérard, Lyon, France

    C Sebban, T Gargi & P Biron

  4. Département de Pédiatrie, Institut Gustave Roussy, Villejuif, France

    C Patte

Authors
  1. E Jabbour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Koscielny
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Sebban
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Peslin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Patte
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Gargi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Biron
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Fermé
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J H Bourhis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J M Vantelon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P Arnaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. V Ribrag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V Ribrag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jabbour, E., Koscielny, S., Sebban, C. et al. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 20, 814–819 (2006). https://doi.org/10.1038/sj.leu.2404156

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404156

Keywords

This article is cited by

Search

Advanced search

Quick links